Todd Creech, MBA

todd_creech_feature_780x1000px_0.jpg

Todd had spent nine years as a healthcare CFO helping to build several successful companies to profitable exits before joining HealthQuest, excited to bring his operations and financial experiences to innovative companies that are primed for growth with the right plan and execution. He currently serves on the Boards of BioIQ and Vestagen and as a Board Observer for Health Channels and Avedro.

Previously, he had been the CFO for Femasys, a Medtech company developing and selling devices targeting women’s health issues. Prior to that, he was CFO and Treasurer of ZS Pharma (IPO in 2014 and sold to AstraZenaca in 2015; a 30x increase in valuation from when he joined in 2013). Todd was the CFO and led business development activities for Sarcode, the developer of Lifitigrast, the first dry-eye pharmaceutical to be approved (2016) for both signs and symptoms of dry eye (sold to Shire in 2013).  He was also the CFO of Sirion Therapeutics, an ophthalmic company that successfully developed and received approval for two products (Durezol and Virgan) and was sold to Alcon and Bausch and Lomb in 2010. During his CFO tenure he has raised more than $500 million in equity and debt, helping to build operations and companies that generated over $3.5 billion in exits.

Earlier in his career, Todd did healthcare venture investing for Quintiles and worked with SRI International. He has also co-founded two companies; a spectroscopy platform spinout of Duke University (Centice) and a specialty pharmaceutical company (TLC Pharma).

Todd holds bachelor's degrees in Finance and Accounting from Miami (Ohio) University where he was also a scholarship baseball player, and an MBA from Duke University. He is an Executive-in-Residence for Moffitt Cancer Center and sits on the Healthcare Advisory Board for Duke’s Fuqua School of Business. He and his wife live in Tampa, Florida with their two sons, with whom he watches a lot of hockey.